Независимое исследование подтвердило эффективность механизма Ruvidar в гипоксических опухолях

For anyone still pushing the tired narrative that Ruvidar’s dual PDT/PCT mechanism is “handwaving,” a major ACS JCIM paper just dropped — and it obliterates that argument. This isn’t a Theralase paper. It’s independent, peerreviewed, and published May 29, 2026. And it confirms — pointblank — the same mechanistic pillars Ruvidar is built on. 1 Light makes DNAtargeted photochemistry explode in speed The paper shows photoexcitation cuts the PtDNA activation barrier in half (12.25 → 6.2 kcal/mol) and accelerates reaction time from 67 microseconds to 4 nanoseconds . That’s not “theory.” That’s physics. And it’s exactly the oxygenindependent photochemistry Ruvidar uses. 2 DNA intercalation supercharges phototoxicity The DIP ligand intercalates into DNA, causing major bending and elongation of the double helix — structural damage known to stall replication and trigger apoptosis . This is the same ligand architecture used in Ruvidar’s Rupolypyridyl backbone. 3 Intercalation makes photobinding faster When intercalated, the Pt center sits closer to the N7 attack site and forms covalent DNA bonds with a lower barrier (~5.15 kcal/mol) and subnanosecond kinetics . This is a huge advantage in hypoxic tumors where classical PDT fails. 4 The authors explicitly state these mechanisms are oxygenindependent They call it a “strategic advance over classical photodynamic therapy” . That’s the entire commercial thesis behind Ruvidar. 5 Ruvidar is singled out as the clinical proofpoint Ru(II) polypyridyl complexes are highlighted as the most promising PS class, and Ruvidar’s Phase II progress is cited as the leading example in the field .   Bottom Line for Skeptics You can argue about timelines. You can argue about management. But you can’t argue the science anymore. This paper independently validates: - oxygenindependent photochemistry - dual PDT + PCT synergy - DNA intercalationenhanced phototoxicity - Rupolypyridyl superiority - fast photobinding kinetics - mechanistic differentiation vs cisplatin If you’re still calling Ruvidar “just another PDT,” you’re not doing DD — you’re doing denial.     Deep Dive: Why the New ACS JCIM Paper Strongly Reinforces Ruvidar’s Mechanism A major 2026 ACS JCIM publication provides the most detailed theoretical and mechanistic analysis to date of dual PDT/PCT bimetallic assemblies — the same class of Rupolypyridyl systems underlying Ruvidar. Below is a structured breakdown of why this matters for Theralase investors.   1. LightAccelerated DNA Covalent Binding The paper shows that in the triplet excited state, Pt–N7 DNA binding proceeds with a 6.2 kcal/mol barrier, compared to 12.25 kcal/mol in the dark . Reaction times: - Triplet (light): ~4 ns - Ground state (dark): ~67 μs This is a 10,000× acceleration driven purely by photoexcitation — a hallmark of oxygenindependent photochemistry.   2. DNA Intercalation as a Phototoxicity Multiplier The DIP ligand intercalates into DNA and remains stably intercalated for microseconds, causing: These structural distortions are known to stall polymerases and trigger apoptosis . Binding free energy for intercalation: −8.20 kcal/mol (thermodynamically favored) .   3. Intercalation Enhances Photobinding Kinetics When intercalated, the Pt center is preorganized near nucleophilic N7 sites, lowering the activation barrier to ~5.15 kcal/mol and reducing reaction time to ~659 ps . This is faster than groove binding and dramatically increases photoreaction efficiency.   4. Dual PDT + PCT Synergy The Ru center provides: - MLCTdriven ROS generation (Type II PDT) - Tripletstate population enabling PtCl photolabilization - Electronic redistribution that accelerates PtDNA attack The Pt center provides: Together, they form a true dualaction mechanism, not achievable by monometallic systems.   5. Oxygen Independence Confirmed The authors explicitly state these mechanisms are “totally oxygenindependent” and represent a strategic advance over classical PDT . This directly supports Ruvidar’s clinical positioning in hypoxic tumors.   6. Ruvidar Highlighted as the Leading Clinical Example Ru(II) polypyridyl complexes are identified as the most promising photosensitizers, and Ruvidar’s Phase II progress is cited as the field’s major clinical milestone .   Investor Interpretation This paper provides: - Independent validation of Ruvidar’s mechanistic foundation - Detailed kinetic and thermodynamic modeling supporting dual PDT/PCT - Confirmation of oxygenindependent cytotoxicity - Evidence that DNA intercalation enhances phototoxicity - Reinforcement of Ruvidar’s scientific differentiation vs classical PDT and cisplatinlike agents For a company whose value hinges on mechanistic superiority, this is a significant scientific reinforcement.